Molecular Brain Imaging in the Multimodality Era

Multimodality molecular brain imaging encompasses in vivo visualization, evaluation, and measurement of cellular/molecular processes. Instrumentation and software developments over the past 30 years have fueled advancements in multimodality imaging platforms that enable acquisition of multiple complementary imaging outcomes by either combined sequential or simultaneous acquisition. This article provides a general overview of multimodality neuroimaging in the context of positron emission tomography as a molecular imaging tool and magnetic resonance imaging as a structural and functional imaging tool. Several image examples are provided and general challenges are discussed to exemplify complementary features of the modalities, as well as important strengths and weaknesses of combined assessments. Alzheimer's disease is highlighted, as this clinical area has been strongly impacted by multimodality neuroimaging findings that have improved understanding of the natural history of disease progression, early disease detection, and informed therapy evaluation.

[1]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[2]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[3]  J. Detre,et al.  Potentials and Challenges for Arterial Spin Labeling in Pharmacological Magnetic Resonance Imaging , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[5]  Ronald Boellaard,et al.  Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner , 2007, Physics in medicine and biology.

[6]  M. Greicius,et al.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.

[7]  K Fetterly,et al.  Positron emission tomography within a magnetic field using photomultiplier tubes and lightguides. , 1995, Physics in medicine and biology.

[8]  R. Treede,et al.  Human brain mechanisms of pain perception and regulation in health and disease , 2005, European journal of pain.

[9]  W C Eckelman,et al.  Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[11]  Michael V. Green,et al.  PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Norbert Schuff,et al.  A non-parametric approach for co-analysis of multi-modal brain imaging data: Application to Alzheimer's disease , 2006, NeuroImage.

[13]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[14]  Paul M. Thompson,et al.  Staging Alzheimer's disease progression with multimodality neuroimaging , 2011, Progress in Neurobiology.

[15]  D. Paik,et al.  Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma , 2009, Nature Clinical Practice Oncology.

[16]  Habib Zaidi,et al.  Preclinical Multimodality Imaging in Vivo. , 2008, PET clinics.

[17]  Anders M. Dale,et al.  Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy , 2004, NeuroImage.

[18]  André Luxen,et al.  PET radiotracers for molecular imaging in the brain: Past, present and future , 2012, NeuroImage.

[19]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[20]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  M. Weiner,et al.  Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia , 2011, Trends in Neurosciences.

[22]  Richard G. Wise,et al.  Combining fMRI with a Pharmacokinetic Model to Determine Which Brain Areas Activated by Painful Stimulation Are Specifically Modulated by Remifentanil , 2002, NeuroImage.

[23]  L. Shah,et al.  Functional magnetic resonance imaging. , 2010, Seminars in roentgenology.

[24]  Tianzi Jiang,et al.  Changes in hippocampal connectivity in the early stages of Alzheimer's disease: Evidence from resting state fMRI , 2006, NeuroImage.

[25]  R H Huesman,et al.  Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.

[26]  A. Drzezga,et al.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  R. Buckner Memory and Executive Function in Aging and AD Multiple Factors that Cause Decline and Reserve Factors that Compensate , 2004, Neuron.

[28]  Francis Eustache,et al.  The Default Mode Network in Healthy Aging and Alzheimer's Disease , 2011, International journal of Alzheimer's disease.

[29]  K Herholz,et al.  Positron emission tomography imaging in dementia. , 2007, The British journal of radiology.

[30]  M. Laruelle Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  Paul M. Thompson,et al.  Mapping hippocampal and ventricular change in Alzheimer disease , 2004, NeuroImage.

[32]  A. Petiet,et al.  In Vivo Imaging Biomarkers in Mouse Models of Alzheimer's Disease: Are We Lost in Translation or Breaking Through? , 2010, International journal of Alzheimer's disease.

[33]  F. Beekman,et al.  High-resolution tomography of positron emitters with clustered pinhole SPECT , 2010, Physics in medicine and biology.

[34]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[35]  Abraham Z. Snyder,et al.  A default mode of brain function: A brief history of an evolving idea , 2007, NeuroImage.

[36]  J. Lanciego,et al.  Adeno-associated virus liver transduction efficiency measured by in vivo [18F]FHBG positron emission tomography imaging in rodents and nonhuman primates. , 2011, Human gene therapy.

[37]  Anthony Randal McIntosh,et al.  Partial Least Squares (PLS) methods for neuroimaging: A tutorial and review , 2011, NeuroImage.

[38]  E T Bullmore,et al.  Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans , 2011, Molecular Psychiatry.

[39]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[40]  Jeff H Duyn,et al.  Novel frontiers in ultra-structural and molecular MRI of the brain. , 2011, Current opinion in neurology.

[41]  P. Barker,et al.  MR spectroscopy and spectroscopic imaging of the brain. , 2011, Methods in molecular biology.

[42]  R. Buxton Neuroenergetics Review Article , 2022 .

[43]  N. Lassen,et al.  Tracer kinetic methods in medical physiology , 1979 .

[44]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[45]  A. Verma,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .

[46]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[47]  M. Albert,et al.  Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD , 2005, Neurology.

[48]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[49]  Heinrich Lanfermann,et al.  Multimodality Assessment of Brain Tumors and Tumor Recurrence , 2011, The Journal of Nuclear Medicine.

[50]  Jeffrey A. James,et al.  Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.

[51]  Brian J Bacskai,et al.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[53]  B. Hyman,et al.  Imaging amyloid-beta deposits in vivo. , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  Sungho Tak,et al.  NIRS-SPM: statistical parametric mapping for near infrared spectroscopy , 2008, SPIE BiOS.

[55]  Yul-Wan Sung,et al.  Functional magnetic resonance imaging , 2004, Scholarpedia.

[56]  W. Jagust,et al.  Clinical Studies of Cerebral Blood Flow in Alzheimer's Disease , 1997, Annals of the New York Academy of Sciences.

[57]  K. Blennow,et al.  Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.

[58]  Karl J. Friston,et al.  Stochastic Designs in Event-Related fMRI , 1999, NeuroImage.

[59]  Mark Slifstein,et al.  Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: A positron emission tomography study in Papio anubis , 2011, Synapse.

[60]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[61]  D. Townsend Multimodality imaging of structure and function , 2008, Physics in medicine and biology.

[62]  [A simulation study to evaluate the statistical noise and spatial resolution in image reconstruction of emission computed tomography--with respect to the optimization of the filter function in the convolution integral]. , 1986, Radioisotopes.

[63]  Christer Halldin,et al.  Confirmation of Fenfluramine Effect on 5-HT1B Receptor Binding of [11C]AZ10419369 using an Equilibrium Approach , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[64]  D. Sharp,et al.  Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. , 2012, The British journal of psychiatry : the journal of mental science.

[65]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[66]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[67]  R. Petersen,et al.  Aging, Memory, and Mild Cognitive Impairment , 1997, International Psychogeriatrics.

[68]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[69]  David A Boas,et al.  Direct estimation of evoked hemoglobin changes by multimodality fusion imaging. , 2008, Journal of biomedical optics.

[70]  R. Blasberg Imaging Gene Expression and Endogenous Molecular Processes: Molecular Imaging , 2002, Journal of Cerebral Blood Flow and Metabolism.

[71]  K Wienhard,et al.  Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas , 2001, The Lancet.

[72]  R. Gobetto,et al.  Hyperpolarized agents for advanced MRI investigations. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[73]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[74]  B. Hyman,et al.  Imaging Amyloid-β Deposits In Vivo , 2002 .

[75]  P. Thompson,et al.  Diffusion imaging, white matter, and psychopathology. , 2011, Annual review of clinical psychology.

[76]  Costas Balas,et al.  Review of biomedical optical imaging—a powerful, non-invasive, non-ionizing technology for improving in vivo diagnosis , 2009 .

[77]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[78]  Satoshi Minoshima,et al.  Posterior cingulate cortex in Alzheimer's disease , 1994, The Lancet.

[79]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[80]  David A Mankoff,et al.  A definition of molecular imaging. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[81]  S. Cherry,et al.  Simultaneous in vivo positron emission tomography and magnetic resonance imaging , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[82]  D. Schacter,et al.  The Brain's Default Network , 2008, Annals of the New York Academy of Sciences.

[83]  J S Fowler,et al.  Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.

[84]  Randy L. Gollub,et al.  A combined [11C]diprenorphine PET study and fMRI study of acupuncture analgesia , 2008, Behavioural Brain Research.

[85]  B. Hyman,et al.  Transgenic models of Alzheimer’s disease: Learning from animals , 2005, NeuroRX.

[86]  M. Bobinski,et al.  Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease , 1997, Neurobiology of Aging.

[87]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[88]  Mrinmoy De,et al.  Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. , 2011, Advanced drug delivery reviews.

[89]  B. Pichler,et al.  Pre-clinical PET/MR: technological advances and new perspectives in biomedical research , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  P. Matthews,et al.  Neuroimaging: Applications of fMRI in translational medicine and clinical practice , 2006, Nature Reviews Neuroscience.

[91]  Claude Comtat,et al.  Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT , 2007, Journal of Nuclear Medicine.

[92]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[93]  Ramon Casanova,et al.  Biological parametric mapping: A statistical toolbox for multimodality brain image analysis , 2007, NeuroImage.

[94]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[95]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[96]  R Weissleder,et al.  Continuous assessment of perfusion by tagging including volume and water extraction (CAPTIVE): A steady‐state contrast agent technique for measuring blood flow, relative blood volume fraction, and the water extraction fraction , 1998, Magnetic resonance in medicine.

[97]  Keith A. Johnson,et al.  Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.

[98]  K. P. Lindsey,et al.  Partitioning of Physiological Noise Signals in the Brain with Concurrent Near-Infrared Spectroscopy and fMRI , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[99]  Jeffrey A. Fessler,et al.  Advanced three-dimensional tailored RF pulse for signal recovery in T-weighted functional MRI , 2006 .

[100]  E. Karageorgiou,et al.  NEUROIMAGING IN DEMENTIA , 2010, Continuum.

[101]  Vinod Menon,et al.  Functional connectivity in the resting brain: A network analysis of the default mode hypothesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[102]  C. Claussen,et al.  Simultaneous Mr/pet Imaging of the Human Brain: Feasibility Study 1 , 2022 .

[103]  Gian Domenico Iannetti,et al.  Regions of interest analysis in pharmacological fMRI: How do the definition criteria influence the inferred result? , 2008, NeuroImage.

[104]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[105]  Mark Slifstein,et al.  Striatal and extrastriatal dopamine release measured with PET and [18F] fallypride , 2010, Synapse.

[106]  W. Klunk,et al.  Impact of amyloid imaging on drug development in Alzheimer's disease. , 2007, Nuclear medicine and biology.

[107]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[108]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[109]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Douglas C Noll,et al.  Advanced three‐dimensional tailored RF pulse for signal recovery in T2*‐weighted functional magnetic resonance imaging , 2006, Magnetic resonance in medicine.

[111]  John A. Detre,et al.  Clinical neuroimaging using arterial spin-labeled perfusion magnetic resonance imaging , 2007, Neurotherapeutics.

[112]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[113]  K-J Langen,et al.  High resolution BrainPET combined with simultaneous MRI , 2011, Nuklearmedizin.

[114]  Ryan Chamberlain,et al.  Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. , 2011, Current medical imaging reviews.

[115]  J. Streffer,et al.  Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.

[116]  Yannic Waerzeggers,et al.  Mouse models in neurological disorders: applications of non-invasive imaging. , 2010, Biochimica et biophysica acta.

[117]  Costin Tanase,et al.  Loss of cell ion homeostasis and cell viability in the brain: what sodium MRI can tell us. , 2005, Current topics in developmental biology.

[118]  A. Goate,et al.  Molecular genetics of Alzheimer's disease. , 1993, Archives of neurology.

[119]  Bedda L. Rosario,et al.  Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve , 2009, The Journal of Neuroscience.

[120]  B R Rosen,et al.  Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data , 1997, Magnetic resonance in medicine.

[121]  W. Klunk,et al.  Update on amyloid imaging: From healthy aging to Alzheimer’s disease , 2009, Current neurology and neuroscience reports.

[122]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[123]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[124]  G. Delso,et al.  Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR Scanner , 2011, The Journal of Nuclear Medicine.

[125]  Joel S. Karp,et al.  Concurrent CBF and CMRGlc changes during human brain activation by combined fMRI–PET scanning , 2005, NeuroImage.